Search results for "APR"

showing 10 items of 2648 documents

The phototransduction cascade in the isolated chick pineal gland revisited.

2003

It is well established that the isolated chick pineal gland is directly light sensitive and that melatonin synthesis of the gland can be inhibited by exposing the gland to light during scotophase. Since not all the steps of the phototransduction cascade have been clarified to the same extent as in the retina, we have treated isolated chick pineal glands with 90 min of light during scotophase and with drugs that affect key-components of vertebrate phototransduction, i.e., cyclic guanosine monophosphate (cGMP) phosphodiesterase 6 (PDE6), cGMP levels and cGMP-gated calcium channels. The endpoint measured was the activity of the rate-limiting enzyme of melatonin synthesis, arylalkylamine N-acet…

medicine.medical_specialtyLight Signal TransductionArylamine N-AcetyltransferasePhosphodiesterase 3BiologyNitric OxidePineal GlandRetinachemistry.chemical_compoundPineal glandOrgan Culture TechniquesInternal medicinemedicineCyclic AMPAnimalsCyclic adenosine monophosphateNitric Oxide DonorsEnzyme InhibitorsMolecular BiologyCyclic guanosine monophosphateCyclic GMPMelatoninCyclic Nucleotide Phosphodiesterases Type 6Phosphoric Diester HydrolasesGeneral NeurosciencePhosphodiesteraseNatriuretic Peptide C-TypeCyclic Nucleotide Phosphodiesterases Type 3Circadian RhythmCalcium Channel Agonistsmedicine.anatomical_structureEndocrinologychemistry3'5'-Cyclic-AMP PhosphodiesterasesNeurology (clinical)PDE10ACalcium ChannelsZaprinastChickensPhotic StimulationDevelopmental BiologyEndocrine glandBrain research
researchProduct

Enalapril Prophylaxis for Migraine With Aura

2003

medicine.medical_specialtyNeuroscience (all)business.industryMEDLINEMigraine with auraNeurologyInternal medicineAnesthesiamedicineSettore MED/26 - NeurologiaNeurology (clinical)Enalaprilmedicine.symptombusinessmedicine.drugHeadache: The Journal of Head and Face Pain
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Tissue bioaccumulation patterns, xenobiotic biotransformation and steroid hormone levels in Atlantic salmon (Salmo salar) fed a diet containing perfl…

2011

In the present study, groups of juvenile Atlantic salmon (Salmo salar) were fed gelatine capsules containing fish-food spiked with PFOA or PFOS (0.2 mg kg(-1) fish) and solvent (methanol). The capsules were given at days 0, 3 and 6. Blood, liver and whole kidney samples were collected prior to exposure (no solvent control), and at days 2, 5, 8 and 14 after exposure (Note: that day 14 after exposure is equal to 7d recovery period). We report on the differences in the tissue bioaccumulation patterns of PFOS and PFOA, in addition to tissue and compound differences in modulation pattern of biotransformation enzyme genes. We observed that the level of PFOS and PFOA increased in the blood, liver …

medicine.medical_specialtyReceptors SteroidEnvironmental EngineeringHydrocortisoneTranscription GeneticCYP3AEstroneHealth Toxicology and MutagenesisSalmo salarEstroneBiologyKidneyXenobioticschemistry.chemical_compoundInternal medicineMethyltestosteronemedicineCytochrome P-450 CYP1A1Environmental ChemistryAnimalsCytochrome P-450 CYP3ATestosteroneMethyltestosteroneBiotransformationGlutathione TransferaseFluorocarbonsPublic Health Environmental and Occupational HealthPregnane X ReceptorKidney metabolismGeneral MedicineGeneral ChemistryPollutionPerfluorooctaneEndocrinologychemistryAlkanesulfonic AcidsLiverBioaccumulationToxicityCaprylatesXenobioticmedicine.drugChemosphere
researchProduct

Duodenal Signet Ring Cell Carcinoma in a Celiac Patient

2009

Celiac disease results from damage to the small intestinal mucosa due to an inappropriate immune response to a cereal protein. Long-standing or ‘refractory’ celiac disease is associated with an increased risk of autoimmunity and malignancy. We produced a brief literature review starting from a case of duodenal cancer in a celiac patient. The patient with an history of celiac disease since six months presented with acute manifestation of gastric outlet syndrome. A duodenal stricture was diagnosed at upper gastrointestinal endoscopy and confirmed by abdominal computed tomography. He was successfully treated by segmental duodenal resection. In the resected specimens, the diagnosis was duodenal…

medicine.medical_specialtySignet ring cellmedicine.medical_treatmentGastroenterologyInternal medicineSignet ring cell carcinomamedicineCeliac diseaselcsh:RC799-869duodenal cancer celiac sprue adenocarcinomabusiness.industrySignet ring cellGastroenterologymedicine.diseasePancreaticoduodenectomyResectiondigestive system diseasesmedicine.anatomical_structureDuodenal adenocarcinomaPublished: April 2009DuodenumDuodenal CarcinomaDuodenal adenocarcinomaSurgerylcsh:Diseases of the digestive system. GastroenterologySegmental resectionDuodenal cancerbusinessCase Reports in Gastroenterology
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective

2012

Until very recently, treatment for chronic hepatitis C virus (HCV) infection has been based on the combination of two non-viral specific drugs: pegylated interferon-α and ribavirin, which is effective in, overall, about 40%-50% of cases. To improve the response to treatment, novel drugs have been designed to specifically block viral proteins. Multiple compounds are under development, and the approval for clinical use of the first of such direct-acting antivirals in 2011 (Telaprevir and Boceprevir), represents a milestone in HCV treatment. HCV therapeutics is entering a new expanding era, and a highly-effective cure is envisioned for the first time since the discovery of the virus in 1989. H…

medicine.medical_specialtybusiness.industryPublic healthHepatitis C virusRibavirinAntiviral therapymedicine.disease_causeVirologyResponse to treatmentVirusTelaprevirchemistry.chemical_compoundchemistryBoceprevirmedicineMinireviewbusinessmedicine.drugWorld Journal of Virology
researchProduct

Effects of four different anti-hypertensive treatments on cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with lef…

2000

medicine.medical_specialtybusiness.industryStress testingCardiac arrhythmiaLeft ventricular hypertrophymedicine.diseaseAtenololBlood pressureInternal medicineHeart rateInternal MedicinemedicineCardiologyVerapamilEnalaprilbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Health Policy Model: Long-Term Predictive Results Associated with the Management of HCV-Induced Diseases in Italy

2014

Background: This study is aimed at describing the epidemiological and economic burden that HCV will generate in the next few years in Italy. Furthermore, the impact that future anti-HCV treatments may have on the burden of disease was considered. The analysis has been developed over the period 2013-2030 from the Italian National Health Service (NHS) perspective.Methods: A published system dynamic model was adapted for Italy in order to quantify the HCV-infected population, the disease progression and the associated cost from 1950 to 2030. The model structure was based on transition probabilities reflecting the natural history of the disease. In order to estimate the efficacy of current anti…

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationTelaprevirlaw.inventionClinical trialchemistry.chemical_compoundRandomized controlled trialchemistrylawBoceprevirHealth careEmergency medicineEpidemiologymedicineOperations managementbusinesseducationHealth policymedicine.drugSSRN Electronic Journal
researchProduct

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Cas…

2020

Abstract Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

medicine.medical_specialtymedicine.medical_treatmentARNIlcsh:Medicineheart failureCase ReportheartCase Reports030204 cardiovascular system & hematologySacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicineEnalaprilVentricular remodelingReverse remodelingarrhythmic burdenremodelinglcsh:R5-920business.industrylcsh:RGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillatorfailureValsartan030220 oncology & carcinogenesisHeart failureCardiologylcsh:Medicine (General)businessSacubitril Valsartanmedicine.drugClinical Case Reports
researchProduct